Polio and Polio Vaccine

Polio and Polio Vaccine
Epidemiology and Prevention of Vaccine-

Preventable Diseases
National Immunization Program

Centers for Disease Control and Prevention
Revised March 2002
Poliomyelitis
• First described by Michael Underwood
in 1789
• First outbreak described in U.S. in 1843
• 21,000 paralytic cases reported in the

United States in 1952
• Global eradication in near future

Poliovirus
• Enterovirus (RNA)
• Three serotypes: 1, 2, 3
• Minimal heterotypic immunity between

serotypes
• Rapidly inactivated by heat,

formaldehyde, chlorine, ultraviolet
light
Poliomyelitis Pathogenesis
• Entry into mouth
• Replication in pharynx, GI tract, local

lymphatics
• Hematologic spread to lymphatics and

central nervous system
• Viral spread along nerve fibers
• Destruction of motor neurons

Outcomes of poliovirus infection
Asymptomatic Minor non-CNS illness

Aseptic menigitis Paralytic
0 20 40 60 80 100
Percent
Poliovirus Epidemiology
• Reservoir Human
• Transmission Fecal-oral
Oral-oral possible
• Communicability 7-10 days before onset

Virus present in stool
3-6 weeks
Poliomyelitis – United States, 1950-2001*
25000
Inactivated vaccine
20000
15000
Cases
10000 Live oral vaccine
5000 Last indigenous case
0
1950 1956 1962 1968 1974 1980 1986 1992 1998
*2001 provisional data

Poliomyelitis – United States, 1980-2001*
14
VAPP Imported
12
10
Cases
8
6
4
2
0
1980 1984 1988 1992 1996 2000
*2001 provisional data
Poliovirus Vaccine
• 1955 Inactivated vaccine
• 1961 Types 1 and 2 monovalent OPV
• 1962 Type 3 monovalent OPV
• 1963 Trivalent OPV
• 1987 Enhanced IPV (IPV)

Inactivated Polio Vaccine
• Contains 3 serotypes of vaccine virus
• Grown on monkey kidney (Vero) cells
• Inactivated with formaldehyde
• Contains 2-phenoxyethanol,
neomycin, streptomycin, polymyxin B
Oral Polio Vaccine
• Contains 3 serotypes of vaccine virus
• Grown on monkey kidney (Vero) cells
• Contains neomycin and streptomycin
• Shed in stool for up to 6 weeks

following vaccination
Inactivated Polio Vaccine
• Highly effective in producing
immunity to poliovirus
• >90% immune after 2 doses
• Duration of immunity not

known with certainty
Oral Polio Vaccine
• Highly effective in producing
immunity to poliovirus
• 50% immune after 1 dose
• Immunity probably life-long

Polio Vaccination
Recommendations, 1996-1999
• Increased use of IPV (sequential IPV-
OPV schedule) recommended in 1996
• Intended to reduce the risk of vaccine-

associated paralytic polio (VAPP)
• Continued risk of VAPP for contacts

of OPV recipients
Polio Vaccination Recommendations
• Exclusive use of IPV recommended

in 2000
• OPV no longer manufactured or

routinely available in the United
States
• VAPP eliminated
Polio Vaccination Schedule
Age Vaccine Interval
2 months IPV ---
4 months IPV 4 wks
6-18 months IPV 4 wks
4-6 years IPV 4 wks
Schedules that Include
Both IPV and OPV
• Only IPV is available in the United
States
• Schedule begun with OPV should be

completed with IPV
• Any combination of 4 doses of IPV

and OPV by 5 years constitutes a
complete series
Polio Vaccination of Adults
• Routine vaccination of U.S.
residents >18 years of age not
necessary or recommended
• May consider vaccination of

travelers to polio-endemic
countries and selected laboratory
workers
Polio Vaccination of
Unvaccinated Adults
• IPV
• Use standard IPV schedule if

possible (0, 1-2 months, 6-12
months)
• May separate doses by 4 weeks if

accelerated schedule needed
Polio Vaccination of
Previously Vaccinated Adults
• Previously complete series
–administer one dose of IPV
• Incomplete series
–administer remaining doses in
series
–no need to restart series
Polio Vaccine Adverse Reactions
• Rare local reactions (IPV)
• No serious reactions to IPV have

been documented
• Paralytic poliomyelitis (OPV)

Vaccine-Associated Paralytic Polio
• Increased risk in persons >18 years
• Increased risk in persons with

immunodeficiency
• No procedure available for identifying persons

at risk of paralytic disease
• 5-10 cases per year with exclusive use of OPV
• Most cases in healthy children and their

household contacts
Vaccine-Associated Paralytic Polio
(VAPP) 1980-1998
• Healthy recipients of OPV 41%

• Healthy contacts of
OPV recipients 31%
• Community acquired 5%
• Immunodeficient 24%
Polio Vaccine
Contraindications and Precautions
• Serious allergic reaction to
component or following prior dose
• Moderate or severe acute illness

Polio Eradication
• Last case in United States in 1979
• Western Hemisphere certified polio

free in 1994
• Last isolate of type 2 poliovirus in

India in October 1999
• Global eradication goal by 2005

Wild Poliovirus 1988
Wild Poliovirus 2000
Polio Eradication
You Can Help
• Physicians and other health care
professionals needed for short and
long term international assignments
• Assist with surveillance evaluation,

vaccination logistics, field operations
• Details on National Immunization

Program website
National Immunization Program
• Hotline 800.232.2522
• Email [email protected]
• Website www.cdc.gov/nip

Polio and Polio Vaccine

Uploaded by

Copyright:

Available Formats

Polio and Polio Vaccine

Uploaded by

Document Information

Original Description:

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Polio and Polio Vaccine

Uploaded by

Copyright:

Available Formats

Polio and Polio Vaccine

Epidemiology and Prevention of Vaccine-

National Immunization Program

• First outbreak described in U.S. in 1843

• 21,000 paralytic cases reported in the

• Global eradication in near future

• Minimal heterotypic immunity between

• Rapidly inactivated by heat,

• Replication in pharynx, GI tract, local

• Hematologic spread to lymphatics and

• Viral spread along nerve fibers

• Destruction of motor neurons

Asymptomatic Minor non-CNS illness

• Communicability 7-10 days before onset

10000 Live oral vaccine

5000 Last indigenous case

*2001 provisional data

• 1961 Types 1 and 2 monovalent OPV

• 1962 Type 3 monovalent OPV

• 1963 Trivalent OPV

• 1987 Enhanced IPV (IPV)

• Grown on monkey kidney (Vero) cells

• Inactivated with formaldehyde

• Grown on monkey kidney (Vero) cells

• Contains neomycin and streptomycin

• Shed in stool for up to 6 weeks

• >90% immune after 2 doses

• >99% immune after 3 doses

• Duration of immunity not

• 50% immune after 1 dose

• >95% immune after 3 doses

• Immunity probably life-long

• Intended to reduce the risk of vaccine-

• Continued risk of VAPP for contacts

• Exclusive use of IPV recommended

• OPV no longer manufactured or

• Schedule begun with OPV should be

• Any combination of 4 doses of IPV

• May consider vaccination of

• Use standard IPV schedule if

• May separate doses by 4 weeks if

• No serious reactions to IPV have

• Paralytic poliomyelitis (OPV)

• Increased risk in persons with

• No procedure available for identifying persons

• 5-10 cases per year with exclusive use of OPV

• Most cases in healthy children and their

• Healthy recipients of OPV 41%

• Moderate or severe acute illness

• Western Hemisphere certified polio

• Last isolate of type 2 poliovirus in

• Global eradication goal by 2005

• Assist with surveillance evaluation,

• Details on National Immunization

You might also like